Biocryst Pharmaceuticals buy Royal Bank of Canada
Start price
25.09.23
/
50%
€6.95
Target price
25.09.24
€9.44
Performance (%)
-1.61%
Price
11:31
€6.84
Summary
This prediction is currently active. With a performance of -1.61%, the BUY prediction by Royal_Bank_of_Canada is trending in the wrong direction. This prediction currently runs until 25.09.24. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Biocryst Pharmaceuticals | -1.354% | -1.354% |
iShares Core DAX® | -5.585% | -6.284% |
iShares Nasdaq 100 | -7.241% | -13.117% |
iShares Nikkei 225® | -8.933% | -10.904% |
iShares S&P 500 | -6.148% | -7.562% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat